Immunome, Inc. – NASDAQ:IMNM

Immunome stock price today

$10.02
-0.51
-4.93%
Financial Health
0
1
2
3
4
5
6
7
8
9

Immunome stock price monthly change

-21.87%
month

Immunome stock price quarterly change

-21.87%
quarter

Immunome stock price yearly change

+1.54%
year

Immunome key metrics

Market Cap
 678.47M
Enterprise value
 N/A
P/E
 -1.7
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 3.82
PEG ratio
 0.03
EPS
 -17.6
Revenue
 12.68M
EBITDA
 -236.68M
Income
 -232.02M
Revenue Q/Q
 -56.47%
Revenue Y/Y
 436.50%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -1866.13%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Immunome stock price history

Immunome stock forecast

Immunome financial statements

Profit Margin

Immunome, Inc. (NASDAQ:IMNM): Profit margin
Jun 2023 4.26M -5.55M -130.35%
Sep 2023 3.56M -4.34M -121.88%
Dec 2023 3.82M -92.63M -2421.17%
Mar 2024 1.02M -129.49M -12584.27%
IMNM income statement history

Immunome Financials Estimate

Immunome, Inc. (NASDAQ:IMNM): Analyst Estimates
Dec 2023 3.82M -92.63M -2421.17%
Mar 2024 1.02M -129.49M -12584.27%
Oct 2025 1.02M -6.21M -603.61%
Dec 2025 1.02M -6.57M -638.67%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Immunome, Inc. (NASDAQ:IMNM): Debt to assets
Jun 2023 41435000 32.09M 77.46%
Sep 2023 93161000 87.08M 93.48%
Dec 2023 148540000 28.65M 19.29%
Mar 2024 319754000 34.18M 10.69%
IMNM balance sheet history

Cash Flow

Immunome, Inc. (NASDAQ:IMNM): Cash Flow
Jun 2023 -5.66M -340K 0
Sep 2023 -8.61M -36K 60.87M
Dec 2023 -17.45M -30.00M 55.49M
Mar 2024 -11.17M -37.23M 219.44M
IMNM cash flow history

Immunome alternative data

Immunome
Employees

Immunome, Inc. (NASDAQ:IMNM): Employee count
Sep 2023 37
Oct 2023 37
Nov 2023 37
Dec 2023 37
Jan 2024 37
Feb 2024 37
Mar 2024 37
Apr 2024 37
May 2024 37
Jun 2024 62
Jul 2024 62

Immunome other data

Immunome
Hedge Funds Holdings Q1 2023

1.94% -15.36%
of IMNM is owned by hedge funds
15 -11
hedge funds hold IMNM stock
235.23K -1.86M
shares is hold by hedge funds
IMNM hedge funds holdings changes

Immunome
Insider Trading

Immunome, Inc. (NASDAQ:IMNM): Insider trades (number of shares)
Period Buy Sel
May 2024 102000 0
Aug 2024 7000 3524
Sep 2024 0 14380
Nov 2024 136805 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
SIEGALL CLAY B director, officer.. Common Stock 33,943 $9.78 $331,929
Purchase
SIEGALL CLAY B director, officer.. Common Stock 66,057 $9.54 $630,250
Purchase
LECHLEIDER ROBERT officer: Chief Medical Officer
 Common Stock 15,805 $9.48 $149,800
Purchase
TSAI PHILIP officer: Chief Technology Officer
 Common Stock 21,000 $9.43 $198,030
Option
ROSETT MAX officer: Chief Financial Officer
 Stock option (right to buy) 42,000 $1.05 $44,100
Option
ROSETT MAX officer: Chief Financial Officer
 Common Stock 42,000 $1.05 $44,100
Sale
ROSETT MAX officer: Chief Financial Officer
 Common Stock 14,380 $16.01 $230,224
Purchase
BIENAIME JEAN JACQUES director
 Common Stock 7,000 $13.94 $97,608
Option
HIGGINS JACK officer: Chief Scientific Officer
 Stock option (right to buy) 19,524 $1.35 $26,357
Option
HIGGINS JACK officer: Chief Scientific Officer
 Common Stock 19,524 $1.35 $26,357
IMNM insider trading transactions

Immunome
Patents

Patent
Application
Filling date: 30 Jul 2020 Issue date: 1 Sep 2022
Application
Filling date: 4 Jan 2022 Issue date: 28 Jul 2022
Application
Filling date: 2 Oct 2019 Issue date: 6 Jan 2022
Application
Filling date: 17 Oct 2019 Issue date: 11 Nov 2021
Application
Filling date: 17 May 2019 Issue date: 22 Jul 2021
IMNM patents

Immunome
Latest News

Friday, 13 December 2024
marketbeat.com
Monday, 2 December 2024
businesswire.com
Wednesday, 27 November 2024
businesswire.com
Wednesday, 13 November 2024
zacks.com
Tuesday, 5 November 2024
businesswire.com
Friday, 1 November 2024
businesswire.com
Tuesday, 29 October 2024
businesswire.com
Friday, 18 October 2024
businesswire.com
Tuesday, 8 October 2024
businesswire.com
Thursday, 29 August 2024
businesswire.com
Monday, 12 August 2024
zacks.com
Thursday, 27 June 2024
seekingalpha.com
Monday, 20 May 2024
businesswire.com
Friday, 17 May 2024
businesswire.com
Tuesday, 14 May 2024
Zacks Investment Research
Friday, 26 April 2024
Zacks Investment Research
Thursday, 4 April 2024
Zacks Investment Research
Tuesday, 2 April 2024
Seeking Alpha
Wednesday, 7 February 2024
Zacks Investment Research
Friday, 10 November 2023
Business Wire
Monday, 23 October 2023
InvestorPlace
Thursday, 28 September 2023
Seeking Alpha
Friday, 30 June 2023
Zacks Investment Research
Wednesday, 22 March 2023
Zacks Investment Research
Thursday, 9 March 2023
Business Wire
Tuesday, 31 January 2023
Seeking Alpha
Friday, 6 January 2023
Investors Business Daily
The Dog of Wall Street
Thursday, 19 May 2022
Benzinga
Benzinga

Ideas & Opinions

Frequently Asked Questions (FAQ)

  • What's the price of Immunome stock today?

    One share of Immunome stock can currently be purchased for approximately $10.02.

  • When is Immunome's next earnings date?

    Unfortunately, Immunome's (IMNM) next earnings date is currently unknown.

  • Does Immunome pay dividends?

    No, Immunome does not pay dividends.

  • How much money does Immunome make?

    Immunome has a market capitalization of 678.47M.

  • What is Immunome's stock symbol?

    Immunome, Inc. is traded on the NASDAQ under the ticker symbol "IMNM".

  • What is Immunome's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Immunome?

    Shares of Immunome can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Immunome's key executives?

    Immunome's management team includes the following people:

    • Dr. Purnanand Duddu Sarma Pres, Chief Executive Officer & Director(age: 60, pay: $657,440)
    • Ms. Sandra G. Stoneman Esq. Chief Legal Officer, Gen. Counsel & Corporation Sec.(age: 52, pay: $443,430)
    • Dr. Michael J. Morin Ph.D. Chief Scientist(age: 70, pay: $377,110)

  • How many employees does Immunome have?

    As Jul 2024, Immunome employs 62 workers, which is 68% more then previous quarter.

  • When Immunome went public?

    Immunome, Inc. is publicly traded company for more then 4 years since IPO on 2 Oct 2020.

  • What is Immunome's official website?

    The official website for Immunome is immunome.com.

  • Where are Immunome's headquarters?

    Immunome is headquartered at 665 Stockton Drive, Exton, PA.

  • How can i contact Immunome?

    Immunome's mailing address is 665 Stockton Drive, Exton, PA and company can be reached via phone at +61 3213700.

Immunome company profile:

Immunome, Inc.

immunome.com
Exchange:

NASDAQ

Full time employees:

55

Industry:

Biotechnology

Sector:

Healthcare

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

+61 3213700
665 Stockton Drive
Exton, PA 19341

CIK: 0001472012
ISIN: US45257U1088
CUSIP: 45257U108